Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) monotherapy for patients diagnosed with submacular hemorrhage secondary to exudative age-related macular degeneration. Methods: This retrospective, observational study included 49 patients (49 eyes) who initially presented with submacular hemorrhage associated with exudative age-related macular degeneration and who were followed-up for at least 24 months. Only eyes that were treated with intravitreal anti-VEGF monotherapy were included in the study. Best-corrected visual acuity (BCVA) measurements obtained at diagnosis, six months, and the final visit were compared. The associations of BCVA at the final visit with baseline BCVA, BCVA at six months, symptom duration, hemorrhage extent, and central foveal thickness were also analyzed. Results: Over the course of follow-up (mean, 32.1 ± 8.5 months), an average of 5.1 ± 2.2 anti-VEGF injections were administered. Recurrent hemorrhage was noted in 13 eyes (26.5%). The mean logarithm of the minimal angle of resolution BCVA at diagnosis, six months, and the final visit were 1.40 ± 0.52, 0.87 ± 0.64, and 1.03 ± 0.83, respectively. Both baseline BCVA (p = 0.012) and BCVA at six months (p < 0.001) were significantly associated with BCVA at the final visit. Conclusions: Improved visual acuity was maintained for more than two years with intravitreal anti-VEGF monotherapy. BCVA at six months is a useful clinical index to predict long-term visual prognosis.
Abstract
Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) monotherapy for patients diagnosed with submacular hemorrhage secondary to exudative age-related macular degeneration. Methods: This retrospective, observational study included 49 patients (49 eyes) who initially presented with submacular hemorrhage associated with exudative age-related macular degeneration and who were followed-up for at least 24 months. Only eyes that were treated with intravitreal anti-VEGF monotherapy were included in the study. Best-corrected visual acuity (BCVA) measurements obtained at diagnosis, six months, and the final visit were compared. The associations of BCVA at the final visit with baseline BCVA, BCVA at six months, symptom duration, hemorrhage extent, and central foveal thickness were also analyzed. Results: Over the course of follow-up (mean, 32.1 ± 8.5 months), an average of 5.1 ± 2.2 anti-VEGF injections were administered. Recurrent hemorrhage was noted in 13 eyes (26.5%). The mean logarithm of the minimal angle of resolution BCVA at diagnosis, six months, and the final visit were 1.40 ± 0.52, 0.87 ± 0.64, and 1.03 ± 0.83, respectively. Both baseline BCVA (p = 0.012) and BCVA at six months (p < 0.001) were significantly associated with BCVA at the final visit. Conclusions: Improved visual acuity was maintained for more than two years with intravitreal anti-VEGF monotherapy. BCVA at six months is a useful clinical index to predict long-term visual prognosis.
참고문헌 (34)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.363~372 (2006)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results", Ophthalmology, 119, pp.1388~1398 (2012)
- 권윤형, "Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration", Korean Journal of Ophthalmology, 28(5), pp.386~392 (2014), 대한안과학회
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Cho HJ, "Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy", Am J Ophthalmol, 156, pp.524~531 (2013)
- Iacono P, "Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration", Retina, 34, pp.281~287 (2014)
- Shienbaum G, "Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy", Am J Ophthalmol, 155, pp.1009~1013 (2013)
- Stifter E, "Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage", Am J Ophthalmol, 144, pp.886~892 (2007)
- Kim JH, "Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization", Ophthalmology, 121, pp.926~935 (2014)
- McKibbin M, "Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration", Eye (Lond), 24, pp.994~998 (2010)
- Avery RL, "Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration", Retina, 16, pp.183~189 (1996)
- Bressler NM, "Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no.13", Ophthalmology, 111, pp.1993~2006 (2004)
- Scupola A, "Natural history of macular subretinal hemorrhage in age-related macular degeneration", Ophthalmologica, 213, pp.97~102 (1999)
- Bennett SR, "Factors prognostic of visual outcome in patients with subretinal hemorrhage", Am J Ophthalmol, 109, pp.33~37 (1990)
- Hwang JU, "Recurrent submacular hemorrhage in patients with neovascular age-related macular degeneration", Retina, 32, pp.652~657 (2012)
- Holladay JT, "Visual acuity measurements", J Cataract Refract Surg, 30, pp.287~290 (2004)
- Kang SW, "Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography", Br J Ophthalmol, 93, pp.759~764 (2009)
- Kim JH, "Structure of polypoidal choroidal vasculopathy studied by colocalization between tomographic and angiographic lesions", Am J Ophthalmol, 156, pp.974~980 (2013)
- Sato T, "Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy", Retina, 27, pp.589~594 (2007)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Yannuzzi LA, "Idiopathic polypoidal choroidal vasculopathy (IPCV)", Retina, 10, pp.1~8 (1990)
- Ciardella AP, "Polypoidal choroidal vasculopathy", Surv Ophthalmol, 49, pp.25~37 (2004)
- Coscas G, "Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging", Am J Ophthalmol, 158, pp.309~318 (2014)
- Sho K, "Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics", Arch Ophthalmol, 121, pp.1392~1396 (2003)
- Byeon SH, "Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients", Jpn J Ophthalmol, 52, pp.57~62 (2008)
- Koh AH, "Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment", Retina, 33, pp.686~716 (2013)
- Oishi A, "Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results", Am J Ophthalmol, 156, pp.644~651 (2013)
- Sun Young Lee, "The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 22(2), pp.92~99 (2008), 대한안과학회
- Koh A, "EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy", Retina, 32, pp.1453~1464 (2012)
- Yoneyama S, "Genetic and clinical factors associated with reticular pseudodrusen in exudative age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 252, pp.1435~1441 (2014)
- Fujimura S, "Characteristics of fundus autofluorescence and drusen in the fellow eyes of Japanese patients with exudative age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 251, pp.1~9 (2013)
- Kim SW, "Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy", Retina, 31, pp.1904~1911 (2011)